
On November 17, 2026, the US Food and Drug Administration granted accelerated approval to neladalkib (Nelkarmi) for adults with previously treated ALK-positive non-small cell lung cancer, ten days before its November 27 target date. The approval rests on response data from a single-arm study, so a confirmatory trial now carries the weight, which matters to sponsors, trial sites and research offices.
What happened
FDA’s oncology approvals notice, dated 11/17/2026, states that the agency granted accelerated approval to neladalkib (Nelkarmi, Nuvalent, Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC). Eligible patients are those who received one prior ALK tyrosine kinase inhibitor, alectinib, or two or more prior ALK inhibitors plus platinum-based chemotherapy (FDA).
GSK announced the approval the same day, ahead of the FDA’s original November 27, 2026 target action date, and described it as the company’s second lung cancer approval this year (TipRanks, reproducing GSK’s announcement). Reuters reported on November 17 that the agency had granted accelerated approval to GSK’s drug for an advanced form of lung cancer that has progressed after earlier treatments (Reuters via Yahoo News). The FDA notice lists Nuvalent as the sponsor. GSK’s roughly $10.6 billion purchase of Nuvalent was covered by Fierce Biotech.
The pivotal evidence
According to the FDA, the approval is based on ALKOVE-1 (NCT05384626), a multicenter, single-arm, open-label, multi-cohort study. The primary efficacy outcomes were confirmed overall response rate (ORR) and duration of response (DOR) under RECIST v1.1, assessed by blinded independent central review. There was no randomized comparator.
| Prior therapy | Patients | Confirmed ORR (95% CI) | Responders with DOR of 6 months or more | Responders with DOR of 12 months or more |
|---|---|---|---|---|
| Alectinib only | 67 | 49% (37, 62) | 76% | 52% |
| Two or more ALK inhibitors plus platinum chemotherapy | 155 | 32% (24, 40) | 69% | 51% |
Source: FDA approval notice, November 17, 2026. GSK’s announcement adds intracranial response rates of 55% and 26% respectively among patients with measurable central nervous system metastases at baseline. The FDA notice lists hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation and embryo-fetal toxicity under warnings and precautions, and records priority review, breakthrough therapy and orphan drug designations. A summary from Biotech Catalyst reports that patients whose only prior ALK inhibitor was lorlatinib are outside the approved population.
What the accelerated approval pathway requires
Accelerated approval lets FDA approve a drug for a serious condition on an effect on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit, on the condition that the sponsor verifies that benefit afterwards. Response rate and duration of response are the typical endpoints in single-arm oncology studies of this kind. The accelerated approval pathway sits alongside designations such as priority review, compared in the FDA expedited programs guide.
The 2022 Food and Drug Omnibus Reform Act (FDORA) strengthened the pathway: it lets FDA require, when appropriate, that a confirmatory trial be underway before approval, and it created a more streamlined process for withdrawing an accelerated approval when a confirmatory trial fails to verify benefit. FDA’s January 2025 draft guidance, Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial Is Underway, sets out how the agency reads the word “underway” and says it generally intends to require that confirmatory trials be underway before an accelerated approval is granted. FDA’s oncology-specific guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, strongly recommends that the trial be well underway, if not fully enrolled, by the time of the action.
The confirmatory study
The Biotech Catalyst summary identifies the confirmatory study as ALKAZAR (NCT06765109), a phase 3 trial of neladalkib versus alectinib in first-line ALK-positive NSCLC, with about 450 patients and progression-free survival as the primary endpoint. It cites ClinicalTrials.gov for an estimated primary completion in December 2029, and says GSK’s release states that continued approval may depend on verification of clinical benefit in a confirmatory trial. The design differs from the approval basis in two ways: it is randomized with an active comparator, and it tests a clinical endpoint rather than a response rate in a previously treated population.
What it means for researchers, trial sites and sponsors
- Sponsors and regulatory affairs teams. The sequence here, with a single-arm study supporting approval and a randomized trial already registered, is the structure FDA’s guidance describes. Protocols for programs seeking accelerated approval need the confirmatory trial designed, registered and enrolling on a timeline that FDA can see before the action. See the surrogate endpoint validation guide for how such endpoints are justified.
- Trial sites and research offices. Because a progression-free survival endpoint takes years to mature, sites joining a confirmatory trial should plan budgets, contracts and staffing for a long follow-up window; the feasibility assessment guide and site selection guide explain how sponsors judge these.
- Researchers designing future studies. The ORR and DOR figures with blinded central review set the evidentiary reference for later ALK-positive studies in heavily pretreated populations; the wide confidence interval on the alectinib-only cohort (37% to 62%) reflects its 67 patients.
What happens next
ALKAZAR is the study that will determine whether the accelerated approval converts to a traditional one. Per the Biotech Catalyst summary of ClinicalTrials.gov, its primary completion is estimated for December 2029. The prescribing information on Drugs@FDA remains the place to read the full label. For the wider approval framework, see the FDA drug approval process guide.
Sources
- U.S. Food and Drug Administration, FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive NSCLC, November 17, 2026.
- GSK announcement, November 17, 2026, as reproduced by TipRanks.
- Reuters (Kamal Choudhury), FDA grants accelerated approval to GSK’s lung cancer drug, November 17, 2026, via Yahoo News.
- Biotech Catalyst Calendar, FDA approves GSK’s Nelkarmi for ALK lung cancer, 10 days ahead of its target date, November 2026.
- Fierce Biotech, GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer.
- FDA, Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial Is Underway (draft guidance, January 2025), and Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics.







